Last 47 quarters of trend data · Healthcare · Life Science Tools
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 153.81 | 50.79 | — | 30.19 | 37.23 | 27.71 | — | — | 51.53 | 34.99 | — | 67.16 | — | — | 397.11 | 494.08 | 146.70 | — | — | — | 107.99 |
| — | +83.3% | — | — | -27.8% | -20.8% | — | — | — | — | — | -86.4% | — | — | — | — | +35.8% | — | — | — | -13.5% | |
| P/S Ratio | 2.87 | 2.38 | 1.92 | 1.68 | 1.53 | 2.20 | 2.59 | 2.85 | 3.07 | 2.02 | 2.51 | 2.64 | 2.66 | 3.41 | 4.23 | 4.10 | 3.21 | 5.33 | 5.68 | 7.85 | 11.27 |
| — | +8.5% | -25.8% | -41.1% | -50.3% | +8.6% | +3.2% | +7.8% | +15.4% | -40.6% | -40.6% | -35.6% | -17.2% | -36.1% | -25.6% | -47.7% | -71.5% | -48.2% | -33.1% | -27.0% | +7.6% | |
| P/B Ratio | 3.83 | 3.04 | 2.63 | 2.34 | 2.08 | 3.03 | 4.03 | 4.61 | 4.40 | 3.12 | 4.07 | 1.40 | 1.46 | 1.78 | 2.39 | 2.30 | 2.02 | 2.83 | 3.40 | 4.33 | 4.05 |
| — | +0.1% | -34.7% | -49.3% | -52.8% | -2.9% | -1.0% | +228.8% | +201.5% | +75.4% | +70.4% | -39.0% | -27.7% | -37.0% | -29.7% | -46.9% | -50.1% | -21.5% | +7.0% | +21.7% | +18.9% | |
| P/FCF | 12.79 | 10.11 | 7.30 | 6.06 | 13.00 | 147.96 | 13.81 | 10.15 | 51.00 | 12.33 | 11.98 | 13.58 | 15.48 | 17.85 | 20.45 | 36.73 | 21.18 | — | 39.29 | 31.02 | 115.55 |
| — | -93.2% | -47.2% | -40.3% | -74.5% | +1100.0% | +15.3% | -25.2% | +229.5% | -30.9% | -41.4% | -63.0% | -26.9% | — | -47.9% | +18.4% | -81.7% | — | +51.9% | -9.7% | +247.9% | |
| EV / EBITDA | 18.92 | 12.70 | 18.19 | 10.75 | 12.79 | 19.39 | 22.26 | 19.88 | 23.73 | 15.02 | — | 21.52 | 21.90 | 27.99 | 28.56 | 21.99 | 19.08 | 88.15 | 40.73 | 109.66 | 44.42 |
| — | -34.5% | -18.3% | -45.9% | -46.1% | +29.1% | — | -7.6% | +8.4% | -46.3% | — | -2.1% | +14.7% | -68.3% | -29.9% | -79.9% | -57.0% | +103.9% | +25.2% | +49.0% | +27.8% | |
| EV / EBIT | 46.44 | 23.96 | — | 19.29 | 27.82 | 18.99 | 66.98 | 358.63 | 33.27 | 24.59 | — | 50.84 | — | 1883.41 | 247.84 | 85.59 | 50.01 | — | 316.84 | — | 70.29 |
| — | +26.2% | — | -94.6% | -16.4% | -22.8% | — | +605.4% | — | -98.7% | — | -40.6% | — | — | -21.8% | — | -28.8% | — | +667.9% | — | -1.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.5% | 64.9% | 73.2% | 64.2% | 61.5% | 54.6% | 61.8% | 63.3% | 61.3% | 64.0% | 62.1% | 62.5% | 60.4% | 61.6% | 59.7% | 60.4% | 61.9% | 62.1% | 59.6% | 52.3% | 64.6% |
| — | +18.9% | +18.4% | +1.4% | +0.3% | -14.8% | -0.4% | +1.3% | +1.5% | +4.0% | +3.9% | +3.5% | -2.5% | -0.9% | +0.2% | +15.3% | -4.1% | -2.3% | -8.5% | -13.4% | -3.4% | |
| Operating Margin | 7.4% | 11.7% | 4.3% | 12.2% | 7.8% | 5.1% | 2.4% | 9.2% | 6.1% | 9.6% | -460.6% | -0.1% | -0.1% | -1.3% | 0.9% | 6.3% | 6.8% | -9.1% | -0.2% | -4.6% | 11.7% |
| — | +127.2% | +82.4% | +33.2% | +28.2% | -46.4% | +100.5% | +7439.5% | +5472.6% | +831.6% | -49621.8% | -102.0% | -101.7% | +85.6% | +597.9% | +236.4% | -42.0% | -201.8% | -101.7% | -7231.5% | -16.5% | |
| Net Margin | 2.7% | 4.7% | -6.5% | 5.6% | 4.1% | 8.0% | -11.4% | -2.7% | 5.9% | 5.8% | -432.2% | 4.0% | -2.3% | -1.1% | 1.1% | 0.8% | 2.2% | -2.9% | -3.0% | -3.8% | 10.4% |
| — | -40.9% | +43.3% | +309.0% | -31.2% | +36.7% | +97.4% | -167.4% | +356.2% | +637.3% | -39423.1% | +376.3% | -204.1% | +62.0% | +136.3% | +122.1% | -78.6% | -149.9% | -129.3% | +71.7% | +23.4% |
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 3.9% | 1.5% | -2.2% | 2.0% | 1.4% | 2.9% | -4.5% | -1.1% | 2.2% | 2.3% | -92.9% | 0.5% | -0.3% | -0.1% | 0.2% | 0.1% | 0.3% | -0.4% | -0.5% | -0.5% | 0.9% |
| — | -47.1% | +50.9% | +287.8% | -35.8% | +24.7% | +95.1% | -297.8% | +792.4% | +1727.5% | -59431.3% | +351.6% | -191.6% | +62.2% | +134.7% | +122.9% | -62.9% | -175.0% | -147.2% | +54.1% | +34.7% | |
| ROA | 1.6% | 0.7% | -1.0% | 0.8% | 0.6% | 1.1% | -1.6% | -0.4% | 0.8% | 0.8% | -42.8% | 0.3% | -0.2% | -0.1% | 0.1% | 0.1% | 0.2% | -0.2% | -0.2% | -0.3% | 0.6% |
| — | -38.8% | +41.3% | +323.1% | -25.4% | +42.9% | +96.2% | -222.5% | +498.8% | +1007.1% | -46562.8% | +348.7% | -198.8% | +59.2% | +136.9% | +122.1% | -68.0% | -162.8% | -139.0% | +58.7% | +32.5% | |
| ROIC | 4.3% | 1.8% | 0.6% | 1.7% | 1.0% | 0.7% | 0.3% | 1.2% | 0.7% | 1.2% | -42.7% | -0.0% | -0.0% | -0.1% | 0.1% | 0.5% | 0.5% | -0.6% | -0.0% | -0.4% | 1.1% |
| — | +165.0% | +86.1% | +39.7% | +35.9% | -43.2% | +100.8% | +14256.8% | +8896.5% | +1424.1% | -60514.3% | -101.9% | -101.5% | +85.0% | +591.0% | +207.8% | -49.3% | -176.4% | -101.3% | -8005.5% | -5.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.91 | 0.54 | 0.83 | 0.97 | 1.07 | 1.15 | 1.14 | 1.36 | 1.38 | 1.47 | 1.55 | 0.59 | 0.45 | 0.46 | 0.47 | 0.49 | 0.53 | 0.57 | 0.56 | 0.59 | 0.42 |
| — | -53.1% | -26.6% | -28.9% | -22.7% | -22.0% | -26.5% | +132.7% | +208.5% | +219.5% | +226.7% | +20.0% | -14.9% | -19.2% | -15.8% | -16.5% | +24.4% | +34.7% | +55.5% | +66.1% | +15.3% | |
| Debt / EBITDA | 4.04 | 8.00 | 18.26 | 13.22 | 18.01 | 21.90 | 20.24 | 18.77 | 23.27 | 20.05 | — | 26.29 | 21.59 | 23.87 | 19.45 | 15.78 | 16.33 | 61.18 | 23.85 | 53.61 | 19.92 |
| — | -63.5% | -9.8% | -29.6% | -22.6% | +9.2% | — | -28.6% | +7.8% | -16.0% | — | +66.6% | +32.2% | -61.0% | -18.5% | -70.6% | -18.0% | +179.1% | +46.7% | +70.5% | +23.2% | |
| Current Ratio | 1.72 | 2.07 | 1.72 | 1.94 | 2.02 | 0.66 | 0.63 | 0.71 | 0.70 | 1.94 | 2.47 | 2.68 | 2.96 | 2.93 | 2.74 | 2.74 | 2.80 | 2.90 | 2.59 | 2.59 | 11.13 |
| — | +215.2% | +174.1% | +173.1% | +186.3% | -66.2% | -74.6% | -73.5% | -76.2% | -33.7% | -10.1% | -2.4% | +5.5% | +1.1% | +6.1% | +6.1% | -74.8% | -69.2% | -72.2% | -75.7% | -22.4% | |
| Quick Ratio | 1.29 | 1.52 | 1.29 | 1.45 | 1.44 | 0.47 | 0.47 | 0.53 | 0.51 | 1.37 | 1.73 | 1.86 | 2.13 | 2.03 | 1.94 | 1.93 | 2.13 | 2.29 | 2.07 | 2.08 | 10.71 |
| — | +224.6% | +173.7% | +173.9% | +182.6% | -65.6% | -72.7% | -71.5% | -76.0% | -32.6% | -11.0% | -3.5% | +0.2% | -11.7% | -6.3% | -7.1% | -80.2% | -74.7% | -76.9% | -79.6% | -22.0% | |
| Interest Coverage | 1.12 | 2.84 | -0.61 | 2.51 | 1.70 | 4.19 | 1.18 | 0.22 | 2.26 | 2.37 | -144.83 | 2.05 | -0.46 | 0.11 | 0.80 | 2.65 | 3.79 | -4.34 | 0.96 | -1.30 | 6.57 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MLAB stock.
Mesa Laboratories, Inc.'s current P/E is 153.8x. The average P/E over the last 3 quarters is 39.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Mesa Laboratories, Inc.'s current operating margin is 7.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Mesa Laboratories, Inc.'s business trajectory between earnings reports.